Table 1

Clinical outcomes at 30 days: stratified by cardiac biomarkers

EventsTotal cohort (N=917)HsTnI
<5 ng/L
(N=179)
HsTnI
5 ng/L to 99th%tile
(N=231)
HsTnI
≥ 99th%tile
(N=134)
P valueNT-proBNP<125 pg/mL
(N=251)
NT-proBNP 125 to 900 pg/mL
(N=202)
NT-proBNP≥900 pg/mL
(N=93)
P value
All-cause death88 (12.7%)5 (4.3%)16 (8.8%)31 (25.2%)<0.0019 (5.3%)18 (10.5%)26 (31.9%)<0.001
Advanced respiratory support344 (39.7%)43 (25.4%)98 (44.9%)58 (45.7%)<0.00172 (30.2%)92 (48.8%)38 (43.8%)<0.001
Myocardial infarction4 (0.5%)0 (0.0%)0 (0.0%)3 (2.2%)0.010 (0.0%)1 (0.5%)2 (2.2%)0.56
Heart failure12 (1.4%)0 (0.0%)2 (1.1%)6 (4.5%)0.0030 (0.0%)1 (0.7%)6 (6.5%)<0.001
Takotsubo syndrome5 (0.6%)0 (0.0%)1 (0.6%)1 (0.8%)0.581 (0.6%)1 (0.6%)1 (1.1%)0.74
Acute pericarditis1 (0.1%)1 (0.6%)0 (0.0%)0 (0.0%)0.361 (0.4%)0 (0.0%)0 (0.0%)0.56
Stroke9 (1.1%)0 (0.0%)5 (2.3%)2 (1.5%)0.161 (0.5%)2 (1.0%)4 (4.4%)0.016
VTE20 (3.0%)2 (1.1%)5 (2.6%)4 (3.5%)0.343 (1.6%)6 (3.5%)2 (2.2%)0.39
Atrial tachyarrhythmia47 (5.8%)0 (0.0%)10 (4.9%)17 (13.2%)<0.0012 (0.9%)11 (5.9%)14 (15.5%)<0.001
EventsTotal Cohort (N=917)CK
<UNL
(N=657)
CK
UNL to 3 UNL
(N=171)
CK
≥3 UNL
(N=59)
P valueCK-MB
<UNL
(N=427)
CK-MB
UNL to 3 UNL
(N=39)
CK-MB
≥3 UNL
(N=18)
P value
All-cause death88 (12.7%)51 (10.6%)24 (16.4%)12 (23.5%)<0.00125 (7.8%)7 (20.4%)7 (38.9%)<0.001
Advanced respiratory support344 (39.7%)231 (37.0%)82 (50.7%)31 (54.1%)<0.001143 (35.5%)20 (54.2%)9 (56.3%)0.003
Myocardial infarction4 (0.5%)2 (0.3%)1 (0.6%)1 (1.7%)0.310 (0.0%)0 (0.0%)1 (5.6%)<0.001
Heart failure12 (1.4%)8 (1.3%)3 (1.8%)1 (1.7%)0.845 (1.3%)0 (0.0%)1 (5.6%)0.16
Takotsubo syndrome5 (0.6%)3 (0.5%)2 (1.3%)0 (0.0%)0.492 (0.6%)0 (0.0%)0 (0.0%)0.87
Acute pericarditis1 (0.1%)1 (0.2%00 (0.0%)0 (0.0%)0.841 (0.2%)0 (0.0%)0 (0.0%)0.94
Stroke9 (1.1%)7 (1.3%)2 (1.2%)0 (0.0%)0.725 (1.3%)0 (0.0%)1 (5.6%)0.20
VTE20 (3.0%)10 (1.8%)9 (6.9%)2 (4.2%)0.0057 (1.9%)1 (2.9%)1 (5.6%)0.58
Atrial tachyarrhythmia47 (5.8%)27 (4.6%)12 (8.0%)8 (13.9%)0.00114 (3.7%)1 (2.6%)6 (33.8%)<0.0001
  • Number of patients with event and cumulative incidence (parenthesis). Advanced respiratory support was defined as a composite of invasive endotracheal intubation use or high-flow nasal cannula oxygen therapy.

  • CK, creatine kinase; CK-MB, creatine kinase myocardial band; HsTnI, high-sensitive troponin I; NT-proBNP, N-terminal pro-B-type natriuretic peptide; UNL, upper normal limit; VTE, venous thromboembolism.